title: A new 18F-labeled myocardial PET tracer: myocardial uptake after permanent and transient coronary occlusion in rats.
abstract: Conventional myocardial perfusion PET tracers require onsite tracer production because of their short radioactive half-lives. To investigate the potential of a new (18)F-labeled pyridazinone analog ((18)F-BMS-747158-02), we characterized this tracer in a rat model of permanent and transient coronary occlusion using small-animal PET.
  
  
  METHODS
  Myocardial (18)F-BMS-747158-02 distribution in healthy rats (n = 7), rats with transient (3-min) left coronary artery occlusion (n = 11), and rats with permanent left coronary occlusion (n = 11) was analyzed with a dedicated small-animal PET scanner.
  
  
  RESULTS
  Normal hearts demonstrated intense and almost homogeneous tracer uptake throughout the left ventricle for more than 2 h. During permanent coronary occlusion, PET demonstrated perfusion defects, which remained unchanged (37.6% +/- 8.8%, 37.4% +/- 10.2%, and 36.2% +/- 9.8% left ventricle at 15, 45, and 115 min, respectively, after tracer injection). After transient ischemia, the induced defect size decreased significantly after reperfusion (16.2% +/- 9.3%, 6.0% +/- 6.5%, and 1.4% +/- 1.3% left ventricle). Tracer reinjection after transient ischemia resulted in normalization of the induced defect.
  
  
  CONCLUSIONS
  Coronary occlusion yielded distinct myocardial (18)F-BMS-747158-02 uptake defects in the area of ischemia, which demonstrated normalization of activity after reperfusion and reinjection. These promising kinetic parameters may allow for assessment of flow using exercise-rest protocols similar to those used in combination with exercise and rest perfusion SPECT.
authors.affiliation: Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany. higuchi@po2.nsknet.or.jp
authors.forename: Takahiro
authors.initials: T
authors.lastname: Higuchi
authors.forename: Stephan G
authors.initials: SG
authors.lastname: Nekolla
authors.forename: Marc M
authors.initials: MM
authors.lastname: Huisman
authors.forename: Sybille
authors.initials: S
authors.lastname: Reder
authors.forename: Thorsten
authors.initials: T
authors.lastname: Poethko
authors.forename: Ming
authors.initials: M
authors.lastname: Yu
authors.forename: Hans-Jurgen
authors.initials: HJ
authors.lastname: Wester
authors.forename: David S
authors.initials: DS
authors.lastname: Casebier
authors.forename: Simon P
authors.initials: SP
authors.lastname: Robinson
authors.forename: Rene M
authors.initials: RM
authors.lastname: Botnar
authors.forename: Markus
authors.initials: M
authors.lastname: Schwaiger
mesh_terms: D000818:Animals; D054059:Coronary Occlusion / Q000000981:diagnostic imaging* / Q000473:pathology; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics*; D006321:Heart / Q000000981:diagnostic imaging*; D006352:Heart Ventricles / Q000473:pathology; D007511:Ischemia / Q000473:pathology; D007700:Kinetics; D008297:Male; D009206:Myocardium / Q000378:metabolism; D049268:Positron-Emission Tomography / Q000295:instrumentation / Q000379:methods*; D011724:Pyridazines / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury
chemical_list: C525920:BMS 747158-02; D005462:Fluorine Radioisotopes; D011724:Pyridazines; D019275:Radiopharmaceuticals